Silo Pharma Soars On Positive Data For Its Arthritis Drug Candidate

On:

Shares of Silo Pharma, Inc. (SILO) are surging more than 50% Friday morning after the company reported positive data for its drug candidate SPU-21 for the treatment of Arthritis.

The company today announced positive interim data from its dose optimization study of SPU-21 joint homing peptides for subcutaneous administration of anti-arthritic agents.

Silo Pharma said it is pursuing a development plan utilizing its liposomal joint homing peptides as a potential therapy for rheumatoid arthritis (RA).

SILO, currently at $5.21, has traded in the range of $0.17-$12.45 in the last 1 year.

Source: Read Full Article

Lates News:
  1. Bitcoin Falls to Lowest Level in 3 Months As Market Awaits Outcome of FOMC Meeting
  2. Cryptos Rise As Powell Sounds Less Hawkish Than Feared
  3. Arthur Hayes Says BlackRock’s Bitcoin ETF Would Harm Decentralization
  4. Over 70% of Bitcoin's Circulating Supply Held by Long-Term Holders — What This Means For BTC
  5. Snapshot Of World Markets